Off-label use of maraviroc in HIV-1-infected paediatric patients in clinical practice. [artículo]
Por: González Tomé, María Isabel [Pediatría]
.
Colaborador(es): Servicio de Pediatría-Neonatología.
Tipo de material: 
ArtículoEditor: AIDS (London, England), 2015Descripción: 29(16):2155-9.Recursos en línea: Solicitar documento Resumen: Maraviroc (MVC) is not approved for HIV-1-infected paediatric patients. This is the first assessment of the use of MVC-based salvage therapy in vertically HIV-1-infected paediatric patients in clinical settings. The results suggest that MVC-based salvage therapy is useful in children and adolescents with extensive resistance profile leading to maintained virological suppression in up to 88% of the patients with CCR5-tropic virus. The likelihood of treatment success might increase when MVC is combined with other active drugs.
| Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
|---|---|---|---|---|
Artículo
|
PC17204 (Navegar estantería) | Disponible |
Formato Vancouver:
Palladino C, Gómez ML, Soler Palacín P, González Tomé MI, De Ory SJ, Espiau M et al; CoRISpe Working Group. Off-label use of maraviroc in HIV-1-infected paediatric patients in clinical practice. AIDS. 2015 Oct 23;29(16):2155-9.
PMID: 26544580
Contiene 25 referencias
Maraviroc (MVC) is not approved for HIV-1-infected paediatric patients. This is the first assessment of the use of MVC-based salvage therapy in vertically HIV-1-infected paediatric patients in clinical settings. The results suggest that MVC-based salvage therapy is useful in children and adolescents with extensive resistance profile leading to maintained virological suppression in up to 88% of the patients with CCR5-tropic virus. The likelihood of treatment success might increase when MVC is combined with other active drugs.
No hay comentarios para este ejemplar.